Research

CDC GLP-1 Survey: 44% Changed Their Prescribed Use
About 1 in 10 adults reported GLP-1 use. The new CDC report found frequent changes to prescribed use, especially among people taking compounded medicine.
Read article →-

FDA Modernization Act 1997: The Trial Registry Law
The 1997 law required a public drug-trial database. ClinicalTrials.gov opened in 2000; broader results-reporting duties came later.
-

FEHB GLP-1 Coverage 2027: Yes, With a Therapy Rule
Federal plans must still cover at least one GLP-1 for weight management. The new therapy requirement makes the 2027 brochure worth checking before December 14.
-

Semaglutide vs Resmetirom: No Clear Liver Winner
A six-month records study found different changes in weight, liver blood tests and cholesterol. It cannot tell us which medicine protects the liver better.
-

Peptide Evidence Map: Human Study Counts
Among 28 selected compounds with no matching FDA product, 14 had no completed intervention study in the registry search. The study records show what each search found and what it missed.
-

Medicaid GLP-1 Coverage Study: Paid Fills Fell 84%
Four states ended weight-loss coverage. Medicaid-paid prescriptions fell sharply, but the data cannot show who stopped treatment or what happened next.
-

Novocare Wegovy: What's Live and What's Coming
Novo's expanded support program adds a free membership and app around Wegovy. Insured home delivery and rewards points are announced additions, with separate eligibility and launch details.
-

What to Do After Stopping GLP-1: Five Paths
People who stopped without another treatment remained about 4% below their original weight in a new study. Other paths had larger averages, but no result chooses a treatment for you.
-

CagriSema Lower Dose: 19% Loss With Side Effects
REDEFINE 9 found about 19% average weight loss at lower CagriSema doses when counting everyone assigned treatment. Gut symptoms remained common, and close results don't prove equal doses.
-

CVS GLP-1 Study: Savings Fell Short of Drug Costs
CVS found lower medical spending among GLP-1 users, but added drug costs were higher. The plan's budget and a patient's health value are different questions.
-

GLP-1 Insurance Denial Study: One in Three Denied
About one in three initial requests was denied. Half of denials involved plan exclusions or coverage limits, despite patients meeting clinical criteria.
-

HHS Peptide Policy Comments: 104 Share One Letter
The policy is still a draft. Of 115 published comments, 104 use one form letter; medical groups’ opposition letters sit outside that count.
-

Noom Peptides: OpenRx Launches Four Treatments
Noom launched OpenRx with four compounded prescription options. Here is what is available, what remains under review, and where the evidence stops.
-

Semaglutide Binge Eating Study Finds Mixed Results
A Penn trial found improvements in eating control and body-image worries during obesity treatment. The groups did not differ significantly in reductions in binge episodes.
-

STEP 2 Trial Results: Weight and Blood Sugar
For adults with type 2 diabetes, STEP 2 compared two semaglutide doses with placebo. Here’s what its weight and blood-sugar results mean.
-

What Is a Medication Guide? FDA Leaflets Explained
A Medication Guide is a required patient handout for certain medicines. Its name matters: Patient Information and Instructions for Use are different documents.
-

Zepbound for Teens: New Results, Adult Label
New tirzepatide results add evidence for teenagers with obesity. The current U.S. Zepbound label still covers adults.
-

Frederick Sanger Insulin Sequence: What He Solved
Sanger and his colleagues read insulin's building-block order and mapped its chain links. Their 1955 work answered a different question from discovering the hormone or seeing its shape.
-

PT-141 Sildenafil Study: What 19 Men Can Tell Us
A 19-man experiment found a stronger laboratory erection response with the combination. The men already responded to Viagra or Levitra, and the result has limits.
-

Thymosin Alpha 1 COVID Dialysis Trial: Results
The final record lists five COVID-19 infections with thymalfasin and seven with usual care. This small dialysis study does not establish prevention.
Page 1 of 10 · 199 articles